Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound
The company is far from a one-trick pony.
Overview
Eli Lilly (NYSE: LLY) became the first trillion-dollar healthcare stock in 2025, after several years of market-beating returns. The company owes that in part to its weight loss medicine, Zepbound, which is currently one of the best-selling drugs in this area. However, the company will likely face significantly more competition over the next five years. Will Eli Lilly continue producing solid returns, or will it destroy shareholders' wealth? The answer partly depends on Eli Lilly's pipeline progress.
Image source: The Motley Fool.
Eli Lilly's Zepbound is currently the leading medicine in the anti-obesity market largely because it is more effective than its main competitor, Novo Nordisk's (NYSE: NVO) Wegovy. In a head-to-head clinical trial, Zepbound led to a mean weight loss of 20.2% over 72 weeks, versus Wegovy's 13.7%. Zepbound also beat Novo Nordisk's next-gen medicine, CagriSema, in a head-to-head clinical trial run by the Denmark-based pharmaceutical leader in patients who were overweight or obese. There are several interesting Phase 3 assets across the industry. Novo Nordisk is itself testing zenagamtide.
Details
Source
Originally published at www.fool.com.